Home › NDC Lookup › RxCUI directory › RxCUI 2565280

2 ML anifrolumab-fnia 150 MG/ML Injection — RxCUI 2565280

Name: 2 ML anifrolumab-fnia 150 MG/ML Injection (RxCUI 2565280)
Creator: Brian Staiger, PharmD

RxNorm drug concept · Semantic clinical drug

RxCUI 2565280 Semantic clinical drug · SCD ● Current RxNorm concept 2 FDA products 4 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by Dr. Brian Staiger, PharmD

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI2565280

Official name2 ML anifrolumab-fnia 150 MG/ML Injection

Concept typeSemantic clinical drug (SCD)

RxNorm statusCurrent RxNorm concept

Also known asanifrolumab-fnia 300 MG per 2 ML Injection; anifrolumab-fnia 300 MG in 2 ML Injection

FDA products mapped2

Package NDCs mapped4

Reported Medicaid activity (SDUD)10,185 prescriptions · 39 state & territory Medicaid programs · latest period Q4 2025

RxNorm release07/06/2026

Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Anifrolumab-fnia Injection: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist

Saphnelo is a biologic medicine specifically designed for moderate to severe systemic lupus erythematosus, or SLE. It works by blocking a signaling pathway that's overactive in mos...
What exactly is Saphnelo and why has my doctor prescribed it for my lupus?
There are two options. One is an IV infusion given at a clinic or infusion center by a healthcare provider, once every four weeks — each session takes about 30 minutes. The other i...
How will I actually receive this medication — will I have to go to a clinic every time?

📖 Read our full Anifrolumab-fnia Injection guide →

🕸️ Concept Web — How 2 ML anifrolumab-fnia 150 MG/ML Injection Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.

This page's concept 2 ML anifrolumab-fnia 150 MG/ML Injection RxCUI 2565280 Semantic clinical drug · SCD

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

Ingredients 2

The active substance itself — no strength, form, or brand attached yet.
- Anifrolumab 2565265 IN
- Anifrolumab-fnia 2565276 PIN
Brand names 1

The same medicine's trade names. A brand name alone says nothing about strength or form.
- Saphnelo 2565282 BN
Dose forms 9

The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.
- Anifrolumab Injection 2565279 SCDF
- Anifrolumab-fnia Injection 2648738 SCDFP
- Anifrolumab Injectable Product 2565278 SCDG
- Anifrolumab-fnia Injectable Product 2662358 SCDGP
- Anifrolumab Injection [Saphnelo] 2565285 SBDF
- Anifrolumab-fnia Injection [Saphnelo] 2654925 SBDFP
- Saphnelo Injectable Product 2565284 SBDG
- Injection 1649574 DF
- +1 more in this family
Clinical & branded drugs 3

Ingredient + strength + dose form. These are the concepts real FDA products actually carry.
- Anifrolumab-fnia 150 MG/ML 2565277 SCDC
- 2 ML anifrolumab-fnia 150 MG/ML Injection [Saphnelo] 2565286 SBD
- Anifrolumab-fnia 150 MG/ML [Saphnelo] 2565283 SBDC

Showing up to 8 concepts per family — 14 of 15 stored related concepts drawn.

These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

Anifrolumab-fnia 150 MG/ML SCDC · 2565277
Anifrolumab Injection SCDF · 2565279
Anifrolumab-fnia Injection SCDFP · 2648738
Anifrolumab Injectable Product SCDG · 2565278
Anifrolumab-fnia Injectable Product SCDGP · 2662358

Brand-Name Concepts

2 ML anifrolumab-fnia 150 MG/ML Injection [Saphnelo] SBD · 2565286
Anifrolumab-fnia 150 MG/ML [Saphnelo] SBDC · 2565283
Anifrolumab Injection [Saphnelo] SBDF · 2565285
Anifrolumab-fnia Injection [Saphnelo] SBDFP · 2654925
Saphnelo Injectable Product SBDG · 2565284
Saphnelo BN · 2565282

📦 FDA Products & Package NDCs

2 products · 4 package NDCs

4 package NDCs map to RxCUI 2565280 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.

Package NDC	Package	Brand / generic name	Labeler	Marketing start
00310-3040-00	1 VIAL, GLASS in 1 CARTON (0310-3040-00) / 2 mL in 1 VIAL,...	SAPHNELO	AstraZeneca Pharmaceuticals LP	2021-07-30
00310-3080-01	1 SYRINGE, GLASS in 1 CARTON (0310-3080-01) / .8 mL in 1 SY...	SAPHNELO	AstraZeneca Pharmaceuticals LP	2026-04-24
00310-3080-02	1 SYRINGE, GLASS in 1 CARTON (0310-3080-02) / .8 mL in 1 SY...	SAPHNELO	AstraZeneca Pharmaceuticals LP	2026-04-24
00310-3080-95	1 SYRINGE, GLASS in 1 CARTON (0310-3080-95) / .8 mL in 1 SY...	SAPHNELO	AstraZeneca Pharmaceuticals LP	2026-04-24

Observed labelers: AstraZeneca Pharmaceuticals LP (4) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🧾 Billing Codes (HCPCS)

Medical billing codes (HCPCS "J-codes") that connect to this concept's packages — used mostly when a clinic or hospital bills for a drug it administers. Each code links to its full billing page.

Code	Descriptor	Mapped packages	Sources
J0491	Inj anifrolumab-fnia 1mg	1	CMS

⚠ A crosswalk is not coverage: an NDC↔HCPCS mapping does not guarantee any payer covers or pays the code. Always verify the current payer policy before billing.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7

openFDA export observedJul 14, 2026

RxNorm release07/06/2026

Methodology2026-07-full-catalog-v1

A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.

This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.